Multiple previous psoriasis studies evaluating the relative efficacy of biologics have concluded that biologics targeting IL-17A, such as secukinumab and ixekizumab, show superior efficacy compared with IL-12/23 inhibitors, such as ustekinumab; however, safety profiles of both groups have been found to be similar [8,9]. This evidence concerns the gene IL17A and psoriasis.